C02KX02 - search results

volibris 5 mg

glaxo smith kline (israel) ltd - ambrisentan - film coated tablets - ambrisentan 5 mg - ambrisentan - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment with tadalafil.efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.

Israel - English - Ministry of Health

volibris 10 mg

glaxo smith kline (israel) ltd - ambrisentan - film coated tablets - ambrisentan 10 mg - ambrisentan - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment with tadalafil.efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

volibris 5mg tablets

glaxosmithkline uk ltd - ambrisentan - tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

volibris 10mg tablets

glaxosmithkline uk ltd - ambrisentan - tablet - 10mg

European Union - English - EMA (European Medicines Agency)

ambrisentan mylan

mylan s.a.s - ambrisentan - hypertension, pulmonary - antihypertensives, - ambrisentan mylan is indicated for the treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment. efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.ambrisentan mylan is indicated for the treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment. efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.